40
Participants
Start Date
January 31, 2023
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2025
TT-00973-MS tablets treatment
The dose levels to be tested in the dose escalation cohorts are 2, 5, 10, 17, 25, 32, 40 and 50mg QD. All the subjects will receive TT-00973-MS tablets QD until disease progression or occurrence of intolerant adverse reactions.
The First Affiliated Hospital of Bengbu Medical College, Bengbu
Anhui Provincial Hospital, Hefei
Hunan Cancer Hospital, Changsha
TransThera Sciences (Nanjing), Inc.
INDUSTRY